hu.MAP 2.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: HuMAP2_03804
Confidence: Extremely High
Proteins| Genename | Protein Name | Links |
|---|---|---|
| EIF2B5 | Translation initiation factor eIF-2B subunit epsilon (eIF-2B GDP-GTP exchange factor subunit epsilon) | UniProt NCBI |
| EIF2B2 | Translation initiation factor eIF-2B subunit beta (S20I15) (S20III15) (eIF-2B GDP-GTP exchange factor subunit beta) | UniProt NCBI |
| EIF2B4 | Translation initiation factor eIF-2B subunit delta (eIF-2B GDP-GTP exchange factor subunit delta) | UniProt NCBI |
| EIF2B3 | Translation initiation factor eIF-2B subunit gamma (eIF-2B GDP-GTP exchange factor subunit gamma) | UniProt NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| CORUM:7291 | 4.53449095762e-14 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | EIF2B2-EIF2B3-EIF2B4-EIF2B5 complex |
| CORUM:7292 | 2.26724547881e-13 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | EIF2B1-EIF2B2-EIF2B3-EIF2B4-EIF2B5 complex |
| HP:0031212 | 1.02502358622e-12 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal circulating progesterone level |
| HP:0008233 | 1.02502358622e-12 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Decreased circulating progesterone |
| HP:0004485 | 3.07507075865e-12 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Cessation of head growth |
| REAC:R-HSA-72731 | 6.34828734067e-12 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Recycling of eIF2:GDP |
| GO:0005851 | 3.6593342028e-10 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | eukaryotic translation initiation factor 2B complex |
| HP:0008193 | 3.73108585383e-10 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Primary gonadal insufficiency |
| HP:0006808 | 4.8791122704e-10 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Cerebral hypomyelination |
| WP:WP107 | 3.48962594992e-09 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Translation Factors |
| HP:0000751 | 6.45047342807e-09 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Personality changes |
| HP:0007305 | 7.37196963208e-09 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | CNS demyelination |
| HP:0000746 | 1.35395365504e-08 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Delusions |
| HP:0000869 | 1.6861842998e-08 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Secondary amenorrhea |
| HP:0003429 | 2.78295953705e-08 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | CNS hypomyelination |
| HP:0008209 | 4.34355794707e-08 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Premature ovarian insufficiency |
| GO:0014003 | 4.43999216606e-08 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | oligodendrocyte development |
| HP:0031066 | 1.38796393763e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal ovarian physiology |
| HP:0002171 | 3.24231360698e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Gliosis |
| HP:0003621 | 3.76720768501e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Juvenile onset |
| KEGG:03013 | 3.96614904607e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | RNA transport |
| HP:0000786 | 4.35338792326e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Primary amenorrhea |
| GO:0048709 | 4.99499118682e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | oligodendrocyte differentiation |
| REAC:R-HSA-72613 | 6.95938708355e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Eukaryotic Translation Initiation |
| REAC:R-HSA-72737 | 6.95938708355e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Cap-dependent Translation Initiation |
| HP:0000712 | 9.06382231231e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Emotional lability |
| HP:0002354 | 9.06382231231e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Memory impairment |
| HP:0002317 | 9.42637520481e-07 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Unsteady gait |
| HP:0000141 | 1.46788400162e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Amenorrhea |
| HP:0100705 | 1.74159912492e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the glial cells |
| HP:0005484 | 1.92320070865e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Postnatal microcephaly |
| GO:0003743 | 2.47053849812e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | translation initiation factor activity |
| HP:0001254 | 2.5538349898e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Lethargy |
| HP:0002352 | 3.14264338853e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Leukoencephalopathy |
| GO:0021782 | 5.16883395701e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | glial cell development |
| HP:0000140 | 7.38877079368e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the menstrual cycle |
| HP:0000858 | 8.2888942309e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Menstrual irregularities |
| HP:0011400 | 9.06625879338e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal CNS myelination |
| HP:0000137 | 9.68421988792e-06 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the ovary |
| KEGG:05168 | 1.52906522211e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Herpes simplex virus 1 infection |
| HP:0001945 | 2.01913174356e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Fever |
| HP:0000618 | 2.01913174356e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Blindness |
| GO:0008135 | 2.37035812542e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | translation factor activity, RNA binding |
| GO:0009749 | 2.50979095633e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | response to glucose |
| REAC:R-HSA-72766 | 2.61768581314e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Translation |
| GO:0009746 | 2.96515850453e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | response to hexose |
| GO:0034284 | 2.96515850453e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | response to monosaccharide |
| GO:0010001 | 3.47984386015e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | glial cell differentiation |
| HP:0002376 | 3.75530461912e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Developmental regression |
| GO:0009743 | 4.26693005383e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | response to carbohydrate |
| HP:0004372 | 4.43930222269e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Reduced consciousness/confusion |
| GO:0090079 | 5.43019580356e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | translation regulator activity, nucleic acid binding |
| HP:0004370 | 5.44017432617e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of temperature regulation |
| HP:0003117 | 6.87270678133e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal circulating hormone level |
| HP:0040194 | 8.5711013671e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Increased head circumference |
| HP:0000256 | 8.5711013671e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Macrocephaly |
| GO:0042063 | 9.183406566e-05 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | gliogenesis |
| GO:0045182 | 0.000140840088864 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | translation regulator activity |
| HP:0007663 | 0.000145873872068 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Reduced visual acuity |
| HP:0012447 | 0.000162697177255 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal myelination |
| GO:0001541 | 0.000165189908538 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | ovarian follicle development |
| GO:0009408 | 0.000180861495173 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | response to heat |
| HP:0001260 | 0.000242548624119 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Dysarthria |
| HP:0000008 | 0.000279991516971 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of female internal genitalia |
| HP:0031466 | 0.000330462047544 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Impairment in personality functioning |
| GO:0009266 | 0.000373974563235 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | response to temperature stimulus |
| HP:0000812 | 0.000374206923987 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal internal genitalia |
| HP:0000648 | 0.000408013098756 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Optic atrophy |
| HP:0010460 | 0.000455324981017 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the female genitalia |
| HP:0410280 | 0.000494429240297 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Pediatric onset |
| GO:0050852 | 0.000521431948115 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | T cell receptor signaling pathway |
| GO:0005085 | 0.000549708257785 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | guanyl-nucleotide exchange factor activity |
| HP:0100543 | 0.000562168075696 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Cognitive impairment |
| HP:0008373 | 0.000626948027784 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Puberty and gonadal disorders |
| HP:0012795 | 0.00063177999717 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the optic disc |
| GO:0008585 | 0.00064271072446 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | female gonad development |
| GO:0046545 | 0.00064271072446 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | development of primary female sexual characteristics |
| GO:0006413 | 0.000781119283329 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | translational initiation |
| GO:0046660 | 0.00106129291317 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | female sex differentiation |
| GO:0050851 | 0.00117775012637 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | antigen receptor-mediated signaling pathway |
| HP:0000587 | 0.00121006304063 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the optic nerve |
| HP:0001257 | 0.0014019856381 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Spasticity |
| GO:0043434 | 0.00231676827382 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | response to peptide hormone |
| HP:0001288 | 0.00282730763557 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Gait disturbance |
| HP:0000505 | 0.00294848825074 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Visual impairment |
| HP:0001276 | 0.00296390518277 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Hypertonia |
| HP:0001290 | 0.0038337671088 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Generalized hypotonia |
| HP:0002167 | 0.0048599350416 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Neurological speech impairment |
| GO:1901652 | 0.00512711596139 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | response to peptide |
| HP:0003674 | 0.00522808420616 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Onset |
| HP:0000252 | 0.00559185551754 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Microcephaly |
| HP:0040195 | 0.00569198714114 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Decreased head circumference |
| HP:0000504 | 0.00618609857615 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of vision |
| GO:0002429 | 0.00629241325149 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | immune response-activating cell surface receptor signaling pathway |
| HP:0001098 | 0.00648647361662 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal fundus morphology |
| HP:0004329 | 0.00657025917884 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal posterior eye segment morphology |
| HP:0002493 | 0.00730043254718 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Upper motor neuron dysfunction |
| HP:0000818 | 0.00795942553801 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the endocrine system |
| GO:0002768 | 0.008399180142 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | immune response-regulating cell surface receptor signaling pathway |
| GO:0008406 | 0.00898751047669 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | gonad development |
| HP:0012243 | 0.00904814940852 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal reproductive system morphology |
| GO:0042552 | 0.00950554068334 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | myelination |
| GO:0045137 | 0.00950554068334 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | development of primary sexual characteristics |
| GO:0007272 | 0.0106004966657 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | ensheathment of neurons |
| GO:0008366 | 0.0106004966657 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | axon ensheathment |
| HP:0012337 | 0.011050835072 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal homeostasis |
| HP:0007364 | 0.0114711725498 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Aplasia/Hypoplasia of the cerebrum |
| HP:0000240 | 0.0136095592172 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of skull size |
| HP:0000078 | 0.0143510578436 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the genital system |
| HP:0000708 | 0.0192037943475 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Behavioral abnormality |
| HP:0031797 | 0.0203581119901 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Clinical course |
| HP:0002977 | 0.0220467109892 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Aplasia/Hypoplasia involving the central nervous system |
| HP:0001252 | 0.0221163688438 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Muscular hypotonia |
| GO:0007548 | 0.0225145500348 | 0.75 | EIF2B4 EIF2B5 EIF2B2 | sex differentiation |
| GO:0051020 | 0.0236361428963 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | GTPase binding |
| GO:0002757 | 0.0285830601899 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | immune response-activating signal transduction |
| HP:0001250 | 0.0286671857535 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Seizures |
| GO:0007417 | 0.0311799363475 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | central nervous system development |
| HP:0011442 | 0.0318409674551 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of central motor function |
| HP:0002060 | 0.0323945102494 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of the cerebrum |
| HP:0100547 | 0.0340021120767 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of forebrain morphology |
| GO:0002764 | 0.0352384618295 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | immune response-regulating signaling pathway |
| REAC:R-HSA-392499 | 0.0403329683602 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Metabolism of proteins |
| HP:0003808 | 0.044821030766 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormal muscle tone |
| HP:0100022 | 0.0481059688646 | 1.0 | EIF2B4 EIF2B3 EIF2B5 EIF2B2 | Abnormality of movement |
Edges
| Protein 1 | Protein 2 | Score | Precision | Evidence |
|---|---|---|---|---|
| EIF2B3 | EIF2B4 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B2 | EIF2B5 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM boldt Malo fraction boldt_WMM |
| EIF2B2 | EIF2B4 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B2 | EIF2B3 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B5 | EIF2B4 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B5 | EIF2B3 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
Images
Click to enlarge
Complex HuMAP2_03804 has an average edge precision of 0.949 which is ranked 5 out of all 6965 complexes.
Related Complexes
| Genename | Complexes |
|---|---|
| EIF2B5 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B2 | HuMAP2_00931 HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B4 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B3 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |